Search

Background/Aim: Low molecular weight heparin (LMWH) is widely employed to prevent postoperative venous thromboembolism (VTE). This study aimed at analyzing LMWH use and evaluating its efficacy and safety in immediate implantbased post-mastectomy breast reconstruction. Patients and Methods: A monocentric retrospective analysis was conducted on patients who underwent immediate implant-based breast reconstruction (IBR) from January 2021 to December 2023. Preoperative characteristics, Caprini score, type of mastectomy procedure, administration of LMWH, postoperative outcomes, and any adverse events linked to LMWH usage, with particular attention to hematoma or VTE, were collected and analyzed. Results: A total of 211 breast procedures were performed on 179 patients - with a mean age of 50.9 years (SD 12.3) and a mean Caprini score of 6.8 (SD 1.4). In total, 133 patients received LMWH by subcutaneous injection (enoxaparin 40 mg/day) post-operatively and 46 only had mechanical thromboprophylaxis. The overall complication rate was higher but statistically significant in the LMWH group with 27.8% compared to 17.4% in the no-LMWH group (p=0.159). Hematoma occurred in 17 patients (12.8%) in the LMWH group compared to two (4.4%) patients in the no-LMWH group (p=0.164). Moreover, 15 (11.2%) patients who received LMWH required reoperation compared to one (2.2%) in patients who did not receive LMWH (p=0.074). There were no VTE events in either group. Conclusion: There were no significant differences in complications and especially hematoma rate in patients who received LMWH after mastectomy and immediate IBR, compared to patients who did not. Moreover, no difference in VTE rate was observed across groups. [ABSTRACT FROM AUTHOR]

Background/Aim: Breast-conserving surgery is the preferred treatment for early-stage breast cancer but can often result in unsatisfactory cosmetic outcomes. Oncoplastic surgery aims to improve both oncologic and aesthetic outcomes by combining local excision with plastic surgery techniques. Using breast reduction techniques in breast cancer treatment has been shown to allow for wider margins of excision, leading to enhanced oncological safety and reduced recurrence rates without causing significant asymmetry. This study aimed to analyze the surgical and oncological outcomes of a large cohort of patients undergoing oncoplastic reduction mammoplasty (ORM). Patients and Methods: A retrospective analysis of postoperative surgical and oncological outcomes of all patients who underwent ORM at a single center between January 2018 and December 2023 was performed. Preoperative patient characteristics, operative and post-operative outcomes were recorded and analyzed. Results: A total of 67 patients that underwent oncologic breast reduction were included in the final analysis -- representing a total of 71 ORM, with a mean (SD) age of 53.1 (10.5) years and a mean (SD) BMI of 28.8 (5.9) kg/m². A superomedial pedicle-based technique was the most frequently used (36.6%), followed by inferior pedicle-based technique (28.1%). A complication rate of 18.3% on the ipsilateral side was observed. Salvage surgery was necessary in five cases (7.0%) due to positive margins -- with one patient (1.4%) requiring margin expansion surgery and four (5.6%) a completion mastectomy. Conclusion: This monocentric retrospective study shows that ORM is safe, with a complication rate on par with conventional breast reduction and offers satisfactory oncological outcomes. [ABSTRACT FROM AUTHOR]

Simple Summary: Cancer remains a worldwide concern with significant burdens on the population and healthcare systems. Studies have shown that early detection is paramount in positive patient outcomes, although the standard of care screening is limited to a few cancers. When a tumor cell dies, it releases DNA into the bloodstream. This cell-free DNA can be extracted, and specific mutations identified. Technologies based on this principle are gaining popularity amongst physicians for cancer patients to inform personalized treatment. Additionally, if platforms are sensitive enough, blood-based multi-cancer screening can be performed. DEEPGENTM is a next-generation sequencing platform that has been optimized for early cancer detection. This study is a preliminary analysis of cancer detection rates across seven cancers using the DEEPGENTM platform. This is an early clinical analysis of the DEEPGENTM platform for cancer detection. Newly diagnosed cancer patients and individuals with no known malignancy were included in a prospective open-label case-controlled study (NCT03517332). Plasma cfDNA that was extracted from peripheral blood was sequenced and data were processed using machine-learning algorithms to derive cancer prediction scores. A total of 260 cancer patients and 415 controls were included in the study. Overall, sensitivity for all cancers was 57% (95% CI: 52, 64) at 95% specificity, and 43% (95% CI: 37, 49) at 99% specificity. With 51% sensitivity and 95% specificity for all stage 1 cancers, the stage-specific sensitivities trended to improve with higher stages. Early results from this preliminary clinical, prospective evaluation of the DEEPGENTM liquid biopsy platform suggests the platform offers a clinically relevant ability to differentiate individuals with and without known cancer, even at early stages of cancer. [ABSTRACT FROM AUTHOR]

Background: Prepectoral (PP) immediate implant-based breast reconstruction (IBBR) is gaining popularity over the retropectoral (RP) breast reconstruction technique. This study aims to compare complication rates across different body mass index (BMI) groups in patients undergoing PP or RP IBBR., Methods: A monocentric retrospective analysis was conducted on patients who underwent mastectomy and IBBR from January 2018 to December 2023. Preoperative characteristics, BMI, type of mastectomy procedure, PP or RR implant placement, and postoperative outcomes were collected and analyzed., Results: A total of 217 patients were included, representing 276 IBBRs. The overall complication rate on a per breast basis was 26.4%. The overall complication rate did not differ across BMI groups ( P = 0.314) and between PP and RP IBBR ( P = 0.8083). In the PP group, anemia rate increased with low BMI (odds ratio [OR] 0.0215, P = 0.033) and skin complications were more frequent with higher BMI (OR 0.0428, P = 0.0389). In the RP group, higher BMI was correlated with a higher seroma rate in the RP IBBR group (OR 1.2045, P = 0.0334) and a longer hospital length of stay (coefficient 0.248, adjusted R ² 0.082, SD 0.098, P = 0.014)., Conclusions: PP IBBR was associated with a significantly higher rate of anemia in patients with low BMI, and a significantly higher rate of skin complications in high BMI. RP IBBR was associated with higher seroma rate and longer hospital length of stay in patients with higher BMI., Competing Interests: The authors have no financial interest to declare in relation to the content of this article., (Copyright © 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.)

Nipple discharge is a frequent reason for women to consult their physician, led by the fear of cancer. Fortunately, almost 90 % of cases have a benign aetiology. The main challenge is to rule out any malignant pathology by collecting a detailed history and clinical exam in order to define a targeted imaging. The aim of this review is to facilitate the management of nipple discharge. The most common aetiologies of nipple discharge are described, along with a systematic clinical approach to exclude any underlying malignancy and minimize invasive examinations., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

This article tries to facilitate the management of mastalgia. During their lifetime most women will experience breast pain. Many of them will visit a physician for this purpose, often led by the fear of cancer. However, in the absence of other clinical signs such as a lump or nipple discharge, the risk of malignancy remains low. In addition to the patient's medical history and physical examination, an imaging may be necessary. The absence of clinical or radiological abnormalities suffices to reassure patients in most cases. The management of mastalgia is based mainly on diet and life-style changes, the use of a well-suited bra and topical anti-inflammatory medication. In the case of mastalgia not responding to first line treatments, the patient should be referred to a breast-care unit., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.